Search
Login
My Portfolios Login
TradeMachine® Login
CML Research Pro Login
PatternFinder Login
Sign Up
Get TradeMachine®
Get CML Research
Get PatternFinder
Get TradeMachine®
Get CML Research
Get PatternFinder
Compare Products
Home
My Portfolios
CMLViz News
Breaking
Stock
Scanner
Tear Sheet
News
Profile
Stats
Stock Chart
Pivot Points
Financial Charts
Holders
Analysts
Day Trader
Back-Tester
SPX
3,970.99
+26.21
(
+0.66%
)
Dow 30
+0.46%
QQQ
+0.37%
VIX
21.74
-0.87
(
-3.85%
)
Biomarin Pharmaceutical Inc. - Registered Shares
NASDAQ:BMRN
90.74
+0.63
(
+0.70%
)
6:36:43 PM EDT:
$93.32
+2.58 (+2.84%)
Products
FDA Approves First Drug To Improve Growth In Children With Most Common Form Of Dwarfism
Published: 11/19/2021 19:11 GMT
BMRN
Biomarin Pharmaceutical Inc. - Registered Shares (
BMRN
)
- FDA Approves First Drug to Improve Growth in Children With Most Common Form of Dwarfism.
FDA - Granted Approval of Voxzogo (vosoritide) Injection to Biomarin.